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The aim of this study was to directly compare the prognostic value of cumulative scores and composite 
ratios in patients with operable rectal cancer. Within a single surgical unit preoperative differential 
blood cell results including neutrophil (N), lymphocyte (L), monocyte (M) and platelet (P) counts, as 
well as CRP (C) and albumin (A) levels were recorded. These results were used to construct a series 
of composite ratios (NLR, PLR, LMR, CAR) and cumulative scores (NLS, PLS, LMS, NPS, mGPS). 
The relationship between composite ratios and the cumulative scores and clinicopathological 
characteristics, cancer specific survival (CSS) and overall survival (OS) were examined. A total of 413 
patients were included. When adjusted for TNM stage, surgical approach, time of surgery and margin 
involvement mGPS (p < 0.05) was associated with CSS. In addition, most composite ratios/scores 
showed correlations with neoadjuvant therapy (p < 0.001). When a direct comparison between NPS 
(myeloid) and mGPS (liver) was carried out they showed similar associations with both CSS and OS. 
Therefore, both composite ratios and cumulative scores have been shown to be prognostic in patients 
with operable rectal cancer.
Annually there are 1.36 million new cases of colorectal cancer (CRC)  worldwide1. In the UK specifically, colo-
rectal cancer is the fourth most prevalent cancer and the second most common cause of cancer  death2. Rectal 
cancers specifically account for 32% of male CRCs and 23% of female CRCs, making rectal cancer the most 
common GI cancer location below the ileo-caecal  valve2. Overall death rates from colorectal cancer have fallen 
over the last decade, however it is still the case that approximately 40% of patients diagnosed colorectal cancer 
will die of their  disease1.
Recently there has been an increase in the use of neoadjuvant chemoradiotherapy (CRT), particularly in 
patients with locally advanced or margin threatening rectal  cancer3. This multi-modal approach, recommended 
by 2019 NICE guidelines has led to more patients being treated non-operatively with close follow up after com-
plete pathological responses (cPR) to CRT 3. Surgical resection still remains the primary curative treatment in the 
majority of cases however the treatment pathway has become more diverse. As a result, there is ongoing interest 
in the identification of patients at a higher risk of developing advanced disease who may benefit from surgical 
resection despite excellent responses to neoadjuvant therapy.
An increase in the systemic inflammatory response can identify patients at an increased risk of disease 
 progression4,5. Indeed in two recent systematic reviews and meta-analyses Dolan and co-workers have shown that 
assessment of the systemic inflammation has prognostic value in gastrointestinal  cancers4,5. Indeed, in both these 
reviews composite ratios and cumulative scores were the most widely validated means of assessing the systemic 
inflammatory  response4,5. These scores and ratios were constructed from components of the differential white 
blood cell counts assessing the systemic inflammatory response in lymphoid tissue, and acute phase proteins 
assessing the inflammatory response in the  liver6.
In a recent study in 801 patients undergoing surgery for colon cancer Dolan and co-workers directly compared 
cumulative ratios and composite scores including neutrophil/lymphocyte ratio (NLR) and neutrophil lympho-
cyte score (NLS), platelet/lymphocyte ratio (PLR) and platelet lymphocyte score (PLS), lymphocyte/monocyte 
ratio (LMR) and lymphocyte monocyte score (LMS) and C-reactive protein/albumin ratio (CAR) and modified 
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Glasgow Prognositic Score (mGPS)6. This study showed that independent of TNM stage both composite ratios 
and scores had prognostic  value6.
With the recent divergence in the management of rectal cancers with cPR away from surgical resection to 
a more conservative path with watchful waiting treatment regimens, it is increasingly important to accurately 
identify patients at higher risk of developing disseminated disease. To our knowledge the effectiveness of strati-
fication of both composite ratios and cumulative scores has not been assessed in patients with rectal cancer. 
Therefore, the aim of the present study was to compare and contrast the prognostic value of composite ratios 
and cumulative scores, in patients undergoing surgery for rectal cancer.
Patients and methods
Patients were identified from a prospectively maintained database of rectal cancer resections at Glasgow Royal 
Infirmary. Patients who met the following criteria were included. Firstly, those who up to 30 days prior to surgery 
had samples taken for serum CRP, albumin and differential blood cell counts; secondly, those who based on 
preoperative imaging and surgical findings were considered to have undergone potentially curative resection 
for rectal cancer between January 1997 and June 2015. Patients who did not have pre-operative CRP or albumin 
readings, whose cancers were related to inflammatory bowel disease and who underwent surgery for a limited 
resection or for a palliative intent were  excluded7. Pre-operative colonoscopy, MRI rectum and CT thorax, abdo-
men and pelvis was performed in all patients. MRI liver and PET-CT was performed in select patients to confirm 
the extent of disease or if dubiety existed from standard imaging.
The majority of patients with moderate (cT3b or greater, suspicious lymph node within 1 mm of margin or 
extra-mural venous invasion) or high risk (tumour within 1 mm or margin, low tumours encroaching inter-
sphincteric plane or with levator muscle involvement) of local recurrence were offered long-course neo-adjuvant 
chemoradiotherapy (50 Gy radiotherapy in 28 doses with 5-fluorouracil (5-FU) adjuvant chemotherapy) followed 
by TME surgery performed 8–12 weeks post completion.
Staging was based on the fifth edition of the TNM classification, with additional information being taken 
from the resectional pathological reports as  required8. Following diagnosis, all patients were discussed at a mul-
tidisciplinary meeting. A decision on neo-adjuvant therapy or proceeding direct to surgery was made with the 
oncologists coordinating the administration of CRT. Post surgery, 5-FU adjuvant chemotherapy was offered to 
patients with stage III or high-risk stage II disease and no significant comorbidities.
Blood tests were collected and recorded prospectively as mentioned above. Composite ratios and scores were 
constructed as outlined in Table 1. Patients were routinely followed up for 5 years after surgery with 6 monthly 
CEA measurement, annual CT and colonoscopy at 5 years. Both the cancer registration system and Registrar 
General (Scotland) were crosschecked to ensure the cause of death was accurate. The censor date for this study 
was June 30th 2018. Cancer-specific survival (CSS) was measured from date of surgery until date of death from 
recurrent or metastatic rectal cancer. Overall survival (OS) was measured until the date of death from any cause. 
The West of Scotland Research Ethics Committee approved the study and all methods were performed in accord-
ance with relevant guidelines and informed consent was obtained.
Statistics. CRP, albumin and differential blood cell count components were expressed as medians and 
ranges. Receiver operating characteristic (ROC) curve analysis was used to establish cut off values for individual 
ratios. The threshold values of such characteristics were based on the most prominent point on the ROC curve 
for ‘‘sensitivity’’ and ‘‘1-specificity,’’ respectively. The optimal threshold values were defined using the Youden 
index (maximum (sensitivity + specificity − 1)) and these were compared with published validated values to 
determine the value used in the subsequent  analysis9,10. The area under the ROC (AUROC) curve was calcu-
lated. The relationship between NLR, PLR, LMR, CAR, NLS, PLS, LMS and mGPS and both cancer specific and 
overall survival was assessed using Cox proportional hazard regression to calculate hazard ratios (HRs) and 95% 
confidence intervals (95% CIs). The relationship between NLR, PLR, LMR, CAR, NLS, PLS, LMS and mGPS and 
patient clinicopathological characteristics was assessed using Pearson Chi-Square tests. In order not to adjust 
individual variables for multiple comparisons, the correlation of composite ratios and cumulative scores and 
clinicopathological characteristics, a p < 0.001 was considered significant across all variables. This p-value was 
similar to that when a Bonferroni correction was applied (0.05/23 = 0.00217). All analyses were performed using 
SPSS version 22.0 (IBM Corp, Armonk, NY).
Results
A total of 413 patients met the inclusion criteria and were included in the final analysis (Table 2). The majority 
of patients were > 65 (69%), male (57%), BMI > 25 (54%), ASA ≥ 2 (87%), presented electively (99%), underwent 
open resection (83%), had surgery post 2005 (69%) and did not require adjuvant therapy (72%). The majority 
of patients had either TNM stage II or III disease (79%), moderate/well differentiated adenocarcinomas (91%, 
18 of which had mucin lakes), venous invasion (57%), an R0 resection (89%), no peritoneal involvement (91%) 
and no tumour perforation (99%). Over the course of this studies follow up there were 115 (28%) cancer deaths 
and 197 (48%) deaths overall.
The relationship between clinicopathological characteristics and both composite ratios and cumulative scores 
is shown in Table 3 (n = 413). Both composite ratios and cumulative scores showed a correlation with neoadjuvant 
therapy (p < 0.001) and time of surgery (p < 0.001).
The relationship between composite ratios and cumulative scores and their component values were shown 
in Table 4 (n = 413). Both ratios and scores showed that a majority of patients were not systemically inflammed 
prior to surgery (NLR > 5 18%, NLS ≥ 1 48%, PLR > 150 58%, PLS ≥ 1 48%, NPS ≥ 1 11%, CAR > 0.22 28%, 
mGPS ≥ 1 24%).
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The median values for the components of the composite ratios and cumulative scores are shown in Table 4. 
An NLR 3–5 was associated with a median neutrophil and lymphocyte count of 5.1 × 109/l and 1.3 × 109/l respec-
tively, both within normal reference ranges. In contrast, an NLR > 5 was associated with a median neutrophil and 
lymphocyte count of 6.0 × 109/l and 0.8 × 109/l respectively, with lymphocytes being outside the normal reference 
range. A PLR > 150 was associated with a median platelet and lymphocyte count of 277 × 109/l and 1.2 × 109/l 
respectively, both within normal reference ranges. An LMR < 2.4 was associated with a median lymphocyte and 
monocyte count of 1.0 × 109/l and 0.6 × 109/l respectively, both within normal reference ranges. A CAR > 0.22 
was associated with a median CRP concentration of 19 mg/l and a median albumin concentration of 36 g/l, CRP 
being outside the normal reference range.
No correlation between the systemic inflammatory response (mGPS and NPS) and neoadjuvant therapy was 
seen. In addition, Kaplan Meier analysis showed that there was no relationship between neoadjuvant therapy 
and survival in patients undergoing surgery between 1997 and 2015 (p = 0.872). Furthermore, additional Kaplan 
Meier analysis showed no relationship between neoadjuvant therapy and survival in patients undergoing surgery 
between 1997 and 2005 (p = 0.854) or between 2007 and 2015 (p = 0.466).
The relationship between ratios, scores and 5 year cancer specific survival is shown in Table 5 and Figs. 1, 
2, 3 and 4. On ROC analysis using cancer specific survival as an end-point the AUC for TNM stage was 0.622, 
Type of Surgery was 0.575, Time of Surgery was 0.608, NLR was 0.525, NLS was 0.565, PLR was 0.535, PLS was 
0.566, LMR was 0.559, LMS was 0.612, NPS was 0.538, CAR was 0.554 and mGPS was 0.577. When adjusted for 
TNM stage, Type of Surgery, Time of Surgery and Margin Involvement mGPS 2 (p < 0.05) remained associated 
with cancer specific survival.
Table 1.  Systemic inflammation based prognostic ratios and scores.
Neutrophil lymphocyte ratio(NLR)
Neutrophil count:lymphocyte count  ≤ 3
Neutrophil count:lymphocyte count 3–5
Neutrophil count:lymphocyte count  > 5
Neutrophil Lymphocyte Score (NLS)
Neutrophil count ≤ 7.5 × 109/l and lymphocyte count ≥ 1.5 × 109/l 0
Neutrophil count > 7.5 × 109/l and lymphocyte count ≥ 1.5 × 109/l 1
Neutrophil count ≤ 7.5 × 109/l and lymphocyte count < 1.5 × 109/l 1
Neutrophil count > 7.5 × 109/l and lymphocyte count < 1.5 × 109/l 2
Platelet lymphocyte ratio (PLR):
Platelet count:lymphocyte count  ≤ 150
Platelet count:lymphocyte count  > 150
Platelet Lymphocyte Score (PLS)
Platelet count ≤ 400 × 109/l and lymphocyte count ≥ 1.5 × 109/l 0
Platelet count > 400 × 109/l and lymphocyte count ≥ 1.5 × 109/l 1
Platelet count ≤ 400 × 109/l and lymphocyte count < 1.5 × 109/l 1
Platelet count > 400 × 109/l and lymphocyte count < 1.5 × 109/l 2
Lymphocyte monocyte ratio (LMR)
lymphocyte count:monocyte count  ≥ 2.40
lymphocyte count:monocyte count  < 2.40
Lymphocyte Monocyte Score (LMS)
Lymphocyte count ≥ 1.5 × 109/l and monocyte count ≤ 0.80 × 109/l 0
Lymphocyte count < 1.5 × 109/l and monocyte count ≤ 0.80 × 109/l 1
Lymphocyte count >1.5 × 109/l and monocyte count > 0.80 × 109/l 1
Lymphocyte count < 1.5 × 109/l and monocyte count > 0.80 × 109/l 2
Neutrophil Platelet Score (NPS)
Neutrophil count ≤ 7.5 × 109/l and platelet count ≤ 400 × 109/l 0
Neutrophil count > 7.5 × 109/l and platelet count ≤ 400 × 109/l 1
Neutrophil count ≤ 7.5 × 109/l and platelet count > 400 × 109/l 1
Neutrophil count > 7.5 × 109/l and platelet count > 400 × 109/l 2
C-reactive protein albumin ratio (CAR)
C-reactive protein:albumin  ≤ 0.22
C-reactive protein:albumin  > 0.22
Modified Glasgow Prognostic Score (mGPS)
C-reactive protein ≤ 10 mg/l and albumin ≥ 35 g/l 0
C-reactive protein > 10 mg/l and albumin ≥ 35 g/l l 1
C-reactive protein > 10 mg/l and albumin < 35 g/l l 2
4Vol:.(1234567890)
Scientific Reports |        (2020) 10:17965  | https://doi.org/10.1038/s41598-020-73909-0
www.nature.com/scientificreports/
On ROC analysis using overall survival as an end-point the following AUC for TNM stage was 0.596, Type 
of Surgery was 0.614, Time of Surgery was 0.698, NLR was 0.595, NLS was 0.585, PLR was 0.532, PLS was 0.594, 
LMR was 0.590, LMS was 0.589, NPS was 0.569, CAR was 0.549 and mGPS was 0.553. When adjusted for TNM 
stage, Type of Surgery, Time of Surgery and Margin Involvement NLR 3–5 (p < 0.05), NLS 2 (p < 0.05), LMR < 2.4 
(p < 0.05), LMS 1 (p < 0.05) and NPS 1 (p < 0.05), and mGPS 2 (p < 0.01) remained associated with overall survival 
(Table 5 and Figs. 1, 2, 3 and 4).
The prognostic values of the NPS and mGPS were examined in the context of TNM staging in Table 6. 
Within TNM stage II disease the 5-year cancer specific survival rate was 74%. This varied between 77% and 59% 
Table 2.  The clinicopathological characteristics of patients undergoing surgery for rectal cancer (n = 413). 
a n = 336, bn = 298, cn = 405, dn = 393, en = 404, fn = 410, gn = 409, hn = 408, in = 369.
Variables n = 413 (%)
Age (years)
< 65 171 (41.4)
65–74 143 (34.6)
> 75 99 (24.0)
Sex
Female 176 (42.6)
Male 237 (57.4)
BMIa
Underweight 33 (9.8)
Normal 120 (35.7)
Overweight 111 (33.0)
Obese 72 (21.4)
Time of surgery
1997–2004 129 (31.2)
2005–2015 284 (68.8)
ASA  gradeb
1 69 (23.2)
2 128 (43.0)
3 92 (30.9)
4 9 (3.0)
Presentation
Elective 407 (98.5)
Emergency 6 (1.5)
Type of surgery
Open 343 (83.1)
Laparoscopic 70 (16.9)
Neoadjuvant  therapyc
No 305 (75.3)
Yes 100 (24.7)
Adjuvant  therapyd
No 281 (71.5)
Yes 112 (28.5)
T stage
1 42 (10.2)
2 69 (16.7)
3 251 (60.8)
4 51 (12.3)
N stage
0 253 (61.3)
1 114 (27.6)
2 46 (11.1)
TNM stage
1 88 (21.3)
2 161 (39.0)
3 164 (39.7)
Differentiatione
Mod/well 375 (90.8)
Poor 29 (7.2)
Venous  invasionf
No 178 (43.4)
Yes 232 (56.6)
Margin  involvementg
No 364 (89.0)
Yes 45 (11.0)
Peritoneal  involvementh
No 371 (90.9)
Yes 37 (9.1)
Tumour  perforationf
No 404 (98.5)
Yes 6 (1.5)
Surgical  complicationi
No 209 (56.6)
Yes 160 (43.4)
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according to the NPS and between 76% and 68% according to the mGPS. The 5-year overall survival rate was 
56%. This varied between 62% and 23% according to the NPS and between 60% and 46% according to the mGPS.
Within TNM stage III disease the 5 year cancer specific survival rate was 69%. This varied between 70 and 56% 
according to the NPS and between 71 and 58% according to the mGPS. The 5 year overall survival rate was 53%. 
This varied between 56 and 31% according to the NPS and between 56 and 39% according to the mGPS (Table 6).
When those patients who received neoadjuvant treatment were considered only 34 patients died of their 
cancer on follow up. This precluded further meaningful statistical analysis.
Discussion
This study for the first time directly compares the prognostic value of measuring the systemic inflammatory 
response with composite ratios and cumulative scores in patients undergoing surgery for rectal cancer. The results 
are very similar to those reported by Dolan and co-workers in patients with colon cancer which showed that both 
composite ratios and cumulative scores had prognostic value, independent of TNM  stage6. Furthermore, when 
cumulative scores and composite ratios constructed from lymphoid/myeloid tissue or from acute phase proteins 
were compared directly they had similar prognostic  value6. When these results are interpreted together they high-
light the importance of active monitoring of the systemic inflammatory response in patients with rectal cancer.
As has previously been found in colon cancer, ROC curve derived thresholds did not always differentiate 
normal and abnormal values of the individual component parts of the  ratio6. Indeed, as can be seen in Fig. 5a 
when a line of best fit was applied, an NLR > 5 and an NLR > 3 were associated with a median neutrophil count 
of approximately 6.0 and 4.0 respectively, both within the normal reference range. Similar results were found 
for a PLR > 150 and an LMR < 2.4 which were associated with a platelet count of approximately 175 × 109/l and a 
lymphocyte count of 1.2 × 109/l, both within the normal reference range (Fig. 5b,c). As a result, it is apparent that a 
number of composite ratios contain individual readings within normal reference ranges. In addition, when com-
pared with cumulative scores, composite ratios classify more patients as being systemically inflamed (Table 5).
As was the case in patients with colon cancer the results of this study provide further evidence for discontinu-
ing the use of composite ratios to monitor the systemic inflammatory response in patients with rectal  cancer6. 
Indeed, when composite ratios of lymphoid and myeloid cells (NLR) and acute phase proteins (CAR) are plotted 
against each other (Fig. 5e) they do not follow a mirror image pattern. In contrast, when cumulative scores of the 
differential white cell count (NPS) and acute phase proteins (mGPS) were compared directly they showed closer 
agreement for both their systemic inflammatory response status and prognostic value (Table 6). Therefore, the 
use of cumulative score, based on normal reference ranges, builds on a fuller understanding of activation of the 
innate systemic inflammatory response seen in patients with colon  cancer6. In addition cumulative scores have 
a greater level of simplicity and consistency which adds to their clinical relevance in patients with rectal cancer.
Furthermore, a clear correlation between factors associated with poorer survival such sex, BMI, advanced 
T-stage and ASA grades were seen for both higher composite ratios and cumulative scores. This adds further 
weight to the prognostic strength of cumulative scores in particular in patients with rectal cancer. It is of interest 
that there was significant correlation between cumulative scores and composite ratios and patients who under-
went neoadjuvant chemoradiotherapy. This would follow current European clinical practice to offer neoadjuvant 
chemoradiotherapy to patients with locally advanced cancers with an associated increased tumour load and 
inflammatory response. It would also suggest that routine monitoring of the systemic inflammatory response 
will continue to be of increasing importance as management of rectal cancers moves away from a blanket surgical 
approach to one where watchful waiting plays a much more significant  part3.
The present study has a number of possible limitations. Although a relatively large prospective cohort, there 
were small numbers of observations in some sub-group analysis. In addition the time scale of the study crosses 
the change in standard chemotherapy regimes in 2005 to an oxaliplatin based treatment standard. However, it is 
interesting that when entered into cox-regression analysis time of surgery did not prove to be prognostic. Fur-
thermore, data relating to other factors that may have affected markers of the systemic inflammatory response 
such drugs taken prior to sampling were not available. Prior work performed by  Sung11 and  Lee12 have shown the 
predictive values of the NLR & PLR in both pre and post-CRT. Therefore, it would have been interesting to carry 
out further subgroup analysis to assess the prognostic value of both ratios and scores in the pre neoadjuvant CRT 
Table 3.  The correlation between composite ratios and cumulative scores and clinicopathological 
characteristics of patients undergoing elective surgery for rectal cancer (n = 413). *p < 0.001 considered 
significant.
Age Sex BMI
ASA 
grade T-stage N-stage Differentiation
Venous 
invasion
Margin 
involvement
Peritoneal 
involvement
Tumour 
perforation
Neoadjuvant 
therapy
Adjuvant 
therapy
Time of 
surgery
Surgical 
complication
NLR 0.349 0.003 0.050 0.053 0.269 0.234 0.952 0.357 0.007 0.338 0.106  < 0.001 0.466 0.871 0.235
NLS 0.265 0.539 0.024 0.018 0.044 0.785 0.096 0.442 0.019 0.400 0.006  < 0.001 0.646 0.738 0.974
PLR 0.662 0.972 0.004 0.797 0.216 0.366 0.838 0.027 0.184 0.507 0.203  < 0.001 0.724 0.697 0.174
PLS 0.081 0.702 0.010 0.044 0.058 0.559 0.110 0.406 0.042 0.330 0.147  < 0.001 0.319 0.708 0.631
LMR 0.600 0.005 0.005 0.019 0.126 0.063 0.688 0.068 0.066 0.227 0.154  < 0.001 0.319  < 0.001 0.976
LMS 0.768 0.008 0.008 0.471 0.080 0.864 0.007 0.618 0.122 0.137 0.045  < 0.001 0.320  < 0.001 0.914
NPS 0.683 0.023 0.023  < 0.001 0.024 0.885 0.225 0.119 0.002 0.022 0.230 0.944 0.030 0.046 0.664
CAR 0.787 0.873 0.873 0.002 0.005 0.919 0.727 0.262 0.060 0.001 0.772 0.671 0.192  < 0.001 0.672
mGPS 0.893 0.259 0.259  < 0.001 0.009 0.596 0.522 0.140 0.019 0.005 0.215 0.766 0.516 0.131 0.598
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setting in addition to the pre-operative timepoint. However, the available data did not allow for this. Given that 
cancer related inflammation correlates with poor  outcomes13,14, the hope would be that further characterisa-
tion of composite ratios will enable a better prediction model to determine those patients who are more likely 
to have a palliative colorectal cancer as tumour size has been previously shown by De Felice and co-workers15.
In summary, this study for the first time directly compares the prognostic value of measuring the systemic 
inflammatory response with composite ratios and cumulative scores in patients undergoing surgery for rectal 
cancer. The results complement those of a recent study by Dolan and co-workers in colon cancer and show that 
both composite ratios and cumulative scores had prognostic value, independent of TNM stage, surgical approach, 
Table 4.  The relationship between composite ratios and cumulative scores and their component values in 
patients undergoing surgery for rectal cancer (n = 413). a n = 361, bn = 218.
n (%)
Median (range)
Neutrophil Lymphocyte
NLR
 ≤ 3 209 (50.6) 4.0 (1.4–9.9) 2.0 (0.7–6.1)
3–5 130 (31.5) 5.1 (2.0–11.5) 1.3 (0.5–2.4)
 > 5 74 (17.9) 6.0 (2.8–15.4) 0.8 (0.3–1.5)
NLS
0 217 (52.5) 4.4 (2.1–7.5) 2.0 (1.5–6.1)
1 177 (42.9) 4.7 (1.4–11.5) 1.1 (0.3–3.8)
2 19 (4.6) 8.6 (7.6–15.4) 0.9 (0.3–1.4)
n (%)
Median (range)
Platelet Lymphocyte
PLRa
≤ 150 151 (41.8) 234 (125–504) 2.1 (0.9–6.1)
> 150 210 (58.2) 277 (128–648) 1.2 (0.3–3.2)
PLSa
0 187 (51.8) 263 (132–399) 2.0 (1.5–5.0)
1 164 (45.4) 255 (125–648) 1.1 (0.3–6.1)
2 10 (2.8) 426 (404–498) 1.1 (0.6–1.4)
n (%)
Median (range)
Lymphocyte Monocyte
LMRb
≥ 2.4 133 (61.0) 1.8 (0.7–5.0) 0.5 (0.1–1.2)
< 2.4 85 (39.0) 1.0 (0.4–2.5) 0.6 (0.3–1.3)
LMSb
0 105 (48.2) 1.9 (1.5–3.9) 0.6 (0.3–0.8)
1 106 (48.6) 1.0 (0.4–5.0) 5.0 (0.1–1.2)
2 7 (3.2) 0.9 (0.4–1.4) 1.0 (0.9–1.3)
n (%)
Median (range)
Neutrophil Platelet
NPSa
0 320 (88.6) 4.4 (1.6–7.5) 254 (125–399)
1 33 (9.1) 7.8 (3.0–15.4) 362 (207–629)
2 8 (2.2) 8.5 (7.6–10.9) 465 (405–648)
n (%)
Median (range)
CRP Albumin
CAR 
≤ 0.22 298 (72.2) 4.2 (0.1–9.0) 39 (25–52)
> 0.22 115 (27.8) 19 (7.0–208) 36 (18–47)
mGPS
0 314 (76.0) 5 (0.1–10.0) 39 (25–52)
1 58 (14.0) 20 (0.1–112) 39 (34–47)
2 41 (9.9) 24 (11–208) 32 (18–34)
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ROC-AUC 
Univariate
Multivariate Adjusted for 
TNM stage, Type of Surgery 
and Time of Surgery, 
Margin Involvement
ROC-AUC 
Univariate
Multivariate Adjusted 
for TNM stage, Type 
of Surgery and Time 
of Surgery, Margin 
Involvement
CSS
HR (95% CI) p-value
CSS
HR (95% CI) p-value
OS
HR (95% CI) p-value
OS
HR (95% CI) p-value
TNM stage
I (n = 88) 0.622 (0.564–0.680)
0.596 (0.542–
0.651)
II (n = 161) 2.05 (1.06–3.98) 0.034 1.85 (0.89–3.85) 0.098 1.39 (0.89–2.15) 0.144 1.24 (0.75–2.05) 0.395
III (n = 164) 3.22 (1.70–6.13)  < 0.001 2.64 (1.29–5.40) 0.008 1.89 (1.23–2.91) 0.004 1.65 (1.01–2.69) 0.045
Type of surgery
Open (n = 343) 
vs laparoscopic 
(n = 70)
0.575 (0.517–
0.634) 2.51 (1.16–5.41) 0.019 2.05 (0.94–4.67) 0.070
0.614 (0.560–
0.667) 2.48 (1.30–4.72) 0.006 1.84 (0.95–3.60) 0.073
Time to surgery
1997–2004 
(n = 129)
0.608 (0.547–
0.669)
0.698 (0.647–
0.749)
2005–2015 
(n = 284) 0.76 (0.52–1.10) 0.146 0.76 (0.49–1.18) 0.215 0.64 (0.47–0.87) 0.005 0.74 (0.53–1.05) 0.094
Margin involvement
R0 (n = 364) 0.564 (0.499–0.628)
0.532 (0.475–
0.588)
R1 (n = 45) 2.83 (1.79–4.48)  < 0.001 2.59 (1.59–4.21)  < 0.001 1.88 (1.26–2.82) 0.002 1.76 (1.14–2.72) 0.010
Surgical complication
No (n = 209) 0.556 (0.490–0.622)
0.531 (0.472–
0.590)
Yes (n = 160) 1.61 (1.09–2.38) 0.017 1.39 (0.94–2.07) 0.104 1.50 (1.10–2.04) 0.010 1.49 (1.07–2.07) 0.017
NLR/ NLS
NLR < 3 (n = 209) 0.525 (0.463–0.587)
0.595 (0.540–
0.649)
NLR 3–5 (n = 130) 1.25 (0.83–1.89) 0.288 1.18 (0.76–1.84) 0.465 1.44 (1.04–1.99) 0.027 1.45 (1.02–2.05) 0.038
NLR > 5 (n = 74) 1.17 (0.71–1.92) 0.540 0.82 (0.47–1.44) 0.494 1.68 (1.17–2.40) 0.005 1.32 (0.87–1.98) 0.188
NLS 0 (n = 217) 0.565 (0.503–0.627)
0.585 (0.530–
0.640)
NLS 1 (n = 177) 1.49 (1.02–2.17) 0.040 1.40 (0.92–2.12) 0.115 1.39 (1.04–1.87) 0.025 1.33 (0.97–1.84) 0.077
NLS 2 (n = 19) 1.94 (0.88–4.28) 0.101 1.73 (0.76–3.95) 0.191 2.52 (1.46–4.37) 0.001 2.21 (1.22–4.03) 0.009
PLR/ PLS
PLR ≤ 150 
(n = 151)
0.535 (0.468–
0.603)
0.532 (0.472–
0.592)
PLR > 150 
(n = 210) 1.24 (0.81–1.89) 0.324 1.16 (0.73–1.83) 0.536 1.15 (0.83–1.58) 0.403 1.08 (0.76–1.53) 0.676
PLS 0 (n = 187) 0.566 (0.499–0.634)
0.594 (0.535–
0.653)
PLS 1 (n = 164) 1.60 (1.06–2.43) 0.027 1.36 (0.87–2.14) 0.183 1.56 (1.13–2.15) 0.007 1.36 (0.96–1.94) 0.083
PLS 2 (n = 10) 1.24 (0.38–4.01) 0.721 1.06 (0.32–3.57) 0.113 2.01 (0.96–4.18) 0.063 1.47 (0.62–3.50) 0.381
LMR/ LMS
LMR ≥ 2.4 
(n = 133)
0.559 (0.445–
0.673)
0.589 (0.505–
0.673)
LMR < 2.4 (n = 85) 2.22 (1.22–4.04) 0.009 2.08 (1.13–3.845) 0.019 1.78 (1.09–2.91) 0.021 1.73 (1.05–2.83) 0.031
LMS 0 (n = 105) 0.612 (0.517–0.706)
0.592 (0.492–
0.692)
LMS 1 (n = 106) 1.97 (1.03–3.74) 0.039 1.90 (0.99–3.63) 0.054 1.97 (1.16–3.37) 0.013 2.01 (1.17–3.44) 0.011
LMS 2 (n = 7) 2.60 (0.59–11.47) 0.208 2.38 (0.54–10.59) 0.255 2.47 (0.73–8.35) 0.147 2.51 (0.74–8.51) 0.139
NPS
NPS 0 (n = 320) 0.538 (0.468–0.607)
0.569 (0.509–
0.630)
NPS 1 (n = 33) 2.23 (1.28–3.88) 0.005 1.72 (0.92–3.22) 0.087 2.03 (1.30–3.16) 0.002 1.97 (1.22–3.16) 0.005
NPS 2 (n = 8) 0.58 (0.08–4.13) 0.582 0.70 (0.10–5.07) 0.727 2.55 (1.19–5.48) 0.016 2.40 (0.97–5.94) 0.058
CAR/ mGPS
CAR ≤ 0.22 
(n = 298)
0.554 (0.491–
0.617)
0.549 (0.494–
0.605)
CAR > 0.22 
(n = 115) 1.46 (0.99–2.14) 0.053 1.14 (0.75–1.75) 0.541 1.26 (0.94–1.70) 0.127 1.13 (0.81–1.56) 0.483
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ROC-AUC 
Univariate
Multivariate Adjusted for 
TNM stage, Type of Surgery 
and Time of Surgery, 
Margin Involvement
ROC-AUC 
Univariate
Multivariate Adjusted 
for TNM stage, Type 
of Surgery and Time 
of Surgery, Margin 
Involvement
CSS
HR (95% CI) p-value
CSS
HR (95% CI) p-value
OS
HR (95% CI) p-value
OS
HR (95% CI) p-value
mGPS 0 (n = 314) 0.577 (0.513–0.641)
0.553 (0.497–
0.608)
mGPS 1 (n = 58) 1.20 (0.71–2.03) 0.498 1.11 (0.64–1.94) 0.701 1.03 (0.69–1.54) 0.879 1.06 (0.69–1.61) 0.796
mGPS 2 (n = 41) 2.59 (1.61–4.17)  < 0.001 2.09 (1.17–3.72) 0.012 1.79 (1.19–2.69) 0.005 1.56 (0.96–2.53) 0.074
Table 5.  The relationship between validated ratios, scores and survival in patients undergoing surgery for 
rectal cancer (n = 413).
Figure 1.  (a–d) The relationship between the NLR and NLS and both CSS and OS in patients undergoing 
surgery for rectal cancer. Number at risk depicts the number of patients alive or not censored entering each time 
period.
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complications and margin  involvement6. However, as was the case in patients with colon cancer, cumulative 
scores are simpler to construct and more consistent for clinical  use6. Direct comparison of the performance of 
the two variables would be required to definitively characterise their prognostic accuracy in clinical use, however 
these results would suggest that mGPS could be used in the initial workup of patients undergoing neoadjuvant 
therapy for rectal cancer. They could also guide those patients who should be considered for surgical resection 
irrespective of their response to neoadjuvant therapy.
Figure 2.  (a–d) The relationship between the PLR and PLS and both CSS and OS in patients undergoing 
surgery for rectal cancer. Number at risk depicts the number of patients alive or not censored entering each time 
period.
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Figure 3.  (a–d) The relationship between the LMR and LMS and both CSS and OS in patients undergoing 
surgery for rectal cancer. Number at risk depicts the number of patients alive or not censored entering each time 
period.
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Figure 4.  (a–d) The relationship between the CAR and mGPS and both CSS and OS in patients undergoing 
surgery for rectal cancer. Number at risk depicts the number of patients alive or not censored entering each time 
period.
Table 6.  The relationship between mGPS, NLS and 5 year cancer specific survival (CSS) and overall survival 
(OS) rates in patients undergoing potentially curative resection of TNM stage II (n = 137) and III (n = 140) 
rectal cancer. Values are expressed as % (standard error: SE).
mGPS 0 mGPS 1/2 mGPS 0–2 mGPS 0 mGPS 1/2 mGPS 0–2
n
5 year CSS % 
(SE) n
5 year CSS % 
(SE) n 5 year CSS (%) n
5 year OS % 
(SE) n
5 year 
OS % (SE) n
5 year OS % 
(SE)
NPS 0 83 (89%) 77.1 (0.05) 32 (73%) 75.0 (0.08) 115 76.5 (0.04) 83 (89%) 63.9 (0.05) 32 (73%) 56.3 (0.09) 115 61.7 (0.05)
NPS 1/2 10 (11%) 70.0 (0.15) 12 (27%) 50.0 (0.15) 22 59.1 (0.11) 10 (11%) 30.0 (0.15) 12 (27%) 16.7 (0.11) 22 22.7 (0.09)
NPS 0–2 93 76.3 (0.04) 44 68.2 (0.07) 137 73.7 (0.04) 93 60.2 (0.05) 44 45.5 (0.08) 137 55.5 (0.04)
Stage III (n = 140) Stage III (n = 140)
NPS 0 106 (93%) 70.8 (0.04) 18 (69%) 66.7 (0.11) 124 70.2 (0.04) 106 (93%) 57.5 (0.05) 18 (69%) 44.4 (0.12) 124 55.6 (0.05)
NPS 1/2 8 (7%) 75.0 (0.16) 8 (31%) 37.5 (0.18) 16 56.3 (0.13) 8 (7%) 37.5 (0.18) 8 (31%) 25.0 (0.16) 16 31.3 (0.12)
NPS 0–2 114 71.1 (0.04) 26 57.7 (0.10) 140 68.6 (0.04) 114 56.1 (0.05) 26 38.5 (0.10) 140 52.9 (0.04)
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